These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 33238517)

  • 21. XI-011 enhances cisplatin-induced apoptosis by functional restoration of p53 in head and neck cancer.
    Roh JL; Park JY; Kim EH
    Apoptosis; 2014 Nov; 19(11):1594-602. PubMed ID: 25113507
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aspirin plus sorafenib potentiates cisplatin cytotoxicity in resistant head and neck cancer cells through xCT inhibition.
    Roh JL; Kim EH; Jang H; Shin D
    Free Radic Biol Med; 2017 Mar; 104():1-9. PubMed ID: 28057599
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Suppression of SESN1 reduces cisplatin and hyperthermia resistance through increasing reactive oxygen species (ROS) in human maxillary cancer cells.
    Narita N; Ito Y; Takabayashi T; Okamoto M; Imoto Y; Ogi K; Tokunaga T; Matsumoto H; Fujieda S
    Int J Hyperthermia; 2018 Dec; 35(1):269-278. PubMed ID: 30300027
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MiR-520b as a novel molecular target for suppressing stemness phenotype of head-neck cancer by inhibiting CD44.
    Lu YC; Cheng AJ; Lee LY; You GR; Li YL; Chen HY; Chang JT
    Sci Rep; 2017 May; 7(1):2042. PubMed ID: 28515423
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epithelial-mesenchymal transition transcription factor ZEB1/ZEB2 co-expression predicts poor prognosis and maintains tumor-initiating properties in head and neck cancer.
    Chu PY; Hu FW; Yu CC; Tsai LL; Yu CH; Wu BC; Chen YW; Huang PI; Lo WL
    Oral Oncol; 2013 Jan; 49(1):34-41. PubMed ID: 22892238
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hederagenin Induces Apoptosis in Cisplatin-Resistant Head and Neck Cancer Cells by Inhibiting the Nrf2-ARE Antioxidant Pathway.
    Kim EH; Baek S; Shin D; Lee J; Roh JL
    Oxid Med Cell Longev; 2017; 2017():5498908. PubMed ID: 29456786
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
    Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
    Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Activation of microRNA-494-targeting Bmi1 and ADAM10 by silibinin ablates cancer stemness and predicts favourable prognostic value in head and neck squamous cell carcinomas.
    Chang YC; Jan CI; Peng CY; Lai YC; Hu FW; Yu CC
    Oncotarget; 2015 Sep; 6(27):24002-16. PubMed ID: 26090866
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Spindle pole body component 25 homolog expressed by ECM stiffening is required for lung cancer cell proliferation.
    Jeong J; Keum S; Kim D; You E; Ko P; Lee J; Kim J; Kim JW; Rhee S
    Biochem Biophys Res Commun; 2018 Jun; 500(4):937-943. PubMed ID: 29709477
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Knockdown of SET Domain, Bifurcated 1 suppresses head and neck cancer cell viability and wound-healing ability in vitro.
    Özdaş S
    Turk J Biol; 2019; 43(5):281-292. PubMed ID: 31768101
    [TBL] [Abstract][Full Text] [Related]  

  • 31. AKR1C1 controls cisplatin-resistance in head and neck squamous cell carcinoma through cross-talk with the STAT1/3 signaling pathway.
    Chang WM; Chang YC; Yang YC; Lin SK; Chang PM; Hsiao M
    J Exp Clin Cancer Res; 2019 Jun; 38(1):245. PubMed ID: 31182137
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Locally advanced squamous cell carcinoma of the head and neck: A systematic review and Bayesian network meta-analysis of the currently available treatment options.
    Iocca O; Farcomeni A; Di Rocco A; Di Maio P; Golusinski P; Pardiñas López S; Savo A; Pellini R; Spriano G
    Oral Oncol; 2018 May; 80():40-51. PubMed ID: 29706187
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular chaperones as a common set of proteins that regulate the invasion phenotype of head and neck cancer.
    Chiu CC; Lin CY; Lee LY; Chen YJ; Lu YC; Wang HM; Liao CT; Chang JT; Cheng AJ
    Clin Cancer Res; 2011 Jul; 17(14):4629-41. PubMed ID: 21642380
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MicroRNA let-7a represses chemoresistance and tumourigenicity in head and neck cancer via stem-like properties ablation.
    Yu CC; Chen YW; Chiou GY; Tsai LL; Huang PI; Chang CY; Tseng LM; Chiou SH; Yen SH; Chou MY; Chu PY; Lo WL
    Oral Oncol; 2011 Mar; 47(3):202-10. PubMed ID: 21292542
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting the cancer stem cell marker, aldehyde dehydrogenase 1, to circumvent cisplatin resistance in NSCLC.
    MacDonagh L; Gallagher MF; Ffrench B; Gasch C; Breen E; Gray SG; Nicholson S; Leonard N; Ryan R; Young V; O'Leary JJ; Cuffe S; Finn SP; O'Byrne KJ; Barr MP
    Oncotarget; 2017 Sep; 8(42):72544-72563. PubMed ID: 29069808
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Concurrent chemoradiotherapy (CRT) with S-1 and cisplatin (CDDP) in patients (pts) with locally advanced head and neck cancer (HNC)].
    Tahara M
    Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():167-71. PubMed ID: 16897996
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Poly (ADP-ribose) polymerase inhibitor efficacy in head and neck cancer.
    Heitmann J; Geeleher P; Zuo Z; Weichselbaum RR; Vokes EE; Fetscher S; Seiwert TY
    Oral Oncol; 2014 Sep; 50(9):825-31. PubMed ID: 25017803
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CD44s Induces miR-629-3p Expression in Association with Cisplatin Resistance in Head and Neck Cancer Cells.
    Chikuda J; Otsuka K; Shimomura I; Ito K; Miyazaki H; Takahashi RU; Nagasaki M; Mukudai Y; Ochiya T; Shimane T; Shirota T; Yamamoto Y
    Cancers (Basel); 2020 Apr; 12(4):. PubMed ID: 32244823
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of β-catenin in cisplatin resistance, relapse and prognosis of head and neck squamous cell carcinoma.
    Roy S; Kar M; Roy S; Saha A; Padhi S; Banerjee B
    Cell Oncol (Dordr); 2018 Apr; 41(2):185-200. PubMed ID: 29243047
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bufalin reverses acquired drug resistance by inhibiting stemness in colorectal cancer cells.
    Sun J; Xu K; Qiu Y; Gao H; Xu J; Tang Q; Yin P
    Oncol Rep; 2017 Sep; 38(3):1420-1430. PubMed ID: 28731184
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.